The Shotlee Journal
Browse Shotlee articles about Mounjaro.
Showing 9 / 799 Mounjaro articles
Ireland's HSE shelled out over €500k daily last year on GLP-1 injections like Ozempic and Saxenda for patients on free schemes. With usage surging 33% since 2023, explore the spending breakdown, regional variations, and what this means for access to these diabetes and weight loss treatments. Understand the science, eligibility, and future of drugs like Mounjaro.
GLP-1 medications like Ozempic and Wegovy are transforming weight management, but recent label updates highlight a small yet serious risk of acute pancreatitis. This guide breaks down the symptoms, science, and steps to stay safe. Know the signs to protect your health.
Emma lost 8 stone on Mounjaro but faced a life-threatening gallbladder crisis. Her story highlights rising GLP-1 side effects like gallstones amid surging UK surgeries. This guide unpacks the risks, science, and how to protect your health.
GLP-1 medications like Ozempic and Wegovy have transformed weight management, but reports of gastroparesis and bowel issues have sparked lawsuits. This guide breaks down the science, risks, and practical steps for patients. Learn how to balance benefits with safety through informed strategies.
Novo Nordisk's new Wegovy pill has exploded onto the scene, racking up over 26,000 prescriptions in just its second full week. This needle-free GLP-1 option signals a shift in obesity treatment. Discover the data, science, and patient implications behind this rapid uptake.
At 72, Oprah Winfrey deadlifted her way through her birthday workout, crediting GLP-1 medications like Ozempic alongside strength training for her transformation. Her candid story highlights silencing 'food noise,' the risks of weight regain, and why muscle matters in weight loss. Learn evidence-based lessons for your own journey.
The UK's MHRA has updated guidance on a small but serious risk of acute pancreatitis linked to popular GLP-1 weight-loss drugs like Ozempic, Wegovy, and Mounjaro. With over 1.6 million users, understanding symptoms and reporting is crucial. This guide breaks down the latest data, risks, and management strategies.
GLP-1 medications like semaglutide and tirzepatide deliver impressive weight loss, but what happens when you stop? Pivotal trials reveal significant regain risks, underscoring obesity as a chronic condition. This guide breaks down the evidence and offers practical insights for sustained results.
A recent Danish study in JAMA Internal Medicine highlights higher kidney risks with popular GLP-1 drugs like Ozempic compared to SGLT2 inhibitors. While GLP-1s offer weight loss benefits, understanding these findings is crucial for patients. Learn the science, risks, and how to protect your kidneys.
